A Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (1311.5)
Latest Information Update: 20 Jan 2022
Price :
$35 *
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- Sponsors AbbVie
- 04 Nov 2019 According to an AbbVie media release, data from this trial will be presented at the upcoming 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, November 8-13, in Atlanta.
- 06 Aug 2018 Status changed from active, no longer recruiting to completed.
- 26 Jul 2018 This trial has been completed in Spain, according to European Clinical Trials Database.